![figure1](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41590-020-00808-x/MediaObjects/41590_2020_808_Fig1_HTML.png)
This is the second study published in Nature that demonstrates cross-reactive T-cell immunity. I mentioned the other one here.
This one (SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition) says:
Cross-reactive SARS-CoV-2 peptides revealed pre-existing T cell responses in 81% of unexposed individuals and validated similarity with common cold coronaviruses, providing a functional basis for heterologous immunity in SARS-CoV-2 infection.Â
Leave a Reply